TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Liver metastases are a leading cause of death among patients with metastatic colorectal
cancer. Duration of disease control is short following 2nd-line or later systemic therapy.
Liver-directed therapy such as TACE has a higher response rate and improves progression-free
survival (PFS), but the benefit is still limited. Cancer cells escape ischemic cell death via
autophagy and hypoxia-inducible factor (HIF) activation. We hypothesize that blocking
autophagy and the vascular endothelial growth factor (VEGF) pathway will improve both
response and PFS following TACE.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania